imatinib
novartis
['next study', 'imatinib']
 this waning effect of targeted drugs is known. with increasing time - survival gap will become smaller and smaller. eventually there will be os benefit(small delta/high nnt) adjuvant imatinib in gist is a perfect example. next study will explore 3 vs 5 yr.
Associate Professor, Medical Oncology and BMT unit, Tata Memorial Hospital, Mumbai